测序分枝杆菌与算法确定的耐药结核治疗(SMARTT):一项IV期实用性随机对照患者管理策略试验的研究方案
SMARTT是一项实用性、单盲、随机对照医疗器械试验,在南非自由邦省四个卫生区纳入18岁及以上肺结核RR-TB患者,按1:1随机分为全基因组测序(WGS)引导的自动化治疗推荐策略组与南非国家指南治疗对照组,主要疗效指标为治疗前6个月液体培养阳性时间变化率,并评估治愈率、复发率、无结核生存率、安全性、可行性和卫生经济学。
要点
- WGS引导的自动化治疗推荐策略用于RR-TB个体化治疗,与南非国家指南治疗进行随机对照比较。
- 主要疗效指标为治疗前6个月液体培养阳性时间变化率,次要指标包括治愈率、复发率和无结核生存率。
- 试验同时评估安全性、全省范围实施可行性和患者及卫生系统视角的卫生经济学。
核心结论
- 该试验将为WGS引导的自动化治疗推荐策略用于RR-TB个体化治疗的可行性、安全性、成本和有效性提供重要的真实世界证据。
- 鉴于其实用性,该试验将帮助政策制定者决定是否将下一代测序技术整合到高结核负担地区的常规RR-TB诊疗中。
研究设计与样本
- 实用性、单盲、随机对照医疗器械试验,评估WGS引导的自动化治疗推荐策略用于RR-TB个体化治疗。
- 受试者为18岁及以上、在南非自由邦省五个卫生区中的四个卫生区诊断为肺结核RR-TB的患者。
- 参与者按1:1比例随机分为干预组(WGS引导的自动化治疗推荐策略)或对照组(按南非国家指南进行RR-TB治疗)。
关键数值与推荐
- 主要疗效结局为治疗前6个月液体培养阳性时间变化率所测的细菌学应答。
- 次要疗效结局包括RR-TB治疗完成后前12个月的治愈率、复发率(RR-TB疾病复发)和无结核生存率。
- 其他次要结局包括安全性、该策略在全省范围整合到常规诊疗的可行性,以及从患者和卫生系统视角的卫生经济学评估。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Rifampicin-resistant tuberculosis (RR-TB) remains an important global health problem. Ideally, the complete drug-resistance profile guides individualized treatment for all RR-TB patients, but this is only practised in high-income countries. Implementation of whole genome sequencing (WGS) technologies into routine care in low and middle-income countries has not become a reality due to the expected implementation challenges, including translating WGS results into individualized treatment regimen composition. METHODS: This trial is a pragmatic, single-blinded, randomized controlled medical device trial of a WGS-guided automated treatment recommendation strategy for individualized treatment of RR-TB. Subjects are 18 years or older and diagnosed with pulmonary RR-TB in four of the five health districts of the Free State province in South Africa. Participants are randomized in a 1:1 ratio to either the intervention (a WGS-guided automated treatment recommendation strategy for individualized treatment of RR-TB) or control (RR-TB treatment according to the national South African guidelines). The primary effectiveness outcome is the bacteriological response to treatment measured as the rate of change in time to liquid culture positivity during the first 6 months of treatment. Secondary effectiveness outcomes include cure rate, relapse rate (recurrence of RR-TB disease) and TB free survival rate in the first 12 months following RR-TB treatment completion. Additional secondary outcomes of interest include safety, the feasibility of province-wide implementation of the strategy into routine care, and health economic assessment from a patient and health systems perspective. DISCUSSION: This trial will provide important real-life evidence regarding the feasibility, safety, cost, and effectiveness of a WGS-guided automated treatment recommendation strategy for individualized treatment of RR-TB. Given the pragmatic nature, the trial will assist policymakers in the decision-making regarding the integration of next-generation sequencing technologies into routine RR-TB care in high TB burden settings. TRIAL REGISTRATION: ClinicalTrials.gov NCT05017324. Registered on August 23, 2021.
引用
- Van Rie A, De Vos E, Costa E, et al. Sequencing Mycobacteria and Algorithm-determined Resistant Tuberculosis Treatment (SMARTT): a study protocol for a phase IV pragmatic randomized controlled patient management strategy trial. Trials. 2022. PMID: 36209235. doi:10.1186/s13063-022-06793-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。